NCT04964934: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: ESR1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Endocrine (Hormone Therapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be currently on an aromatase inhibitor (e.g., letrozole or anastrozole) + CDK4/6 inhibitor (e.g., palbociclib/Ibrance or abemaciclib/Verzenio) +/- a luteinizing hormone-releasing hormone (LHRH agonist (e.g., Lupron, Zoladex) as the initial endocrine based treatment for advanced disease
Exclusions: Patients with known, active, uncontrolled, or symptomatic CNS metastases or leptomeningeal disease; Patients with prior treatment of AZD9833, investigational SERDs (selective estrogen receptor degraders), or fulvestrant

Comments are closed.

Up ↑